Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.